These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 36671306)
1. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection. Whitney L; Nesnas J; Planche T Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306 [TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Jiang Y; Sarpong EM; Sears P; Obi EN Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan. Okumura H; Ueyama M; Shoji S; English M J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072 [TBL] [Abstract][Full Text] [Related]
4. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250 [TBL] [Abstract][Full Text] [Related]
5. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis. Stabholz Y; Paul M Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610 [TBL] [Abstract][Full Text] [Related]
6. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. Burton HE; Mitchell SA; Watt M Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314 [TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. Polivkova S; Krutova M; Capek V; Sykorova B; Benes J Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906 [TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Watt M; McCrea C; Johal S; Posnett J; Nazir J Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378 [TBL] [Abstract][Full Text] [Related]
9. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946 [TBL] [Abstract][Full Text] [Related]
10. A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Dubberke ER; Li Q; Obi EN; Turzhitsky V; Siddiqui F; Nathanson BH Open Forum Infect Dis; 2024 Oct; 11(10):ofae524. PubMed ID: 39355263 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972 [TBL] [Abstract][Full Text] [Related]
12. A retrospective budget impact analysis of fidaxomicin treatment for Siefen AC; Kurte MS; Bauer AM; Cornely OA; Wingen-Heimann S; Kron F Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):933-942. PubMed ID: 38712561 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Watt M; Dinh A; Le Monnier A; Tilleul P J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856 [TBL] [Abstract][Full Text] [Related]
16. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209 [TBL] [Abstract][Full Text] [Related]
17. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile. Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999 [TBL] [Abstract][Full Text] [Related]
18. The Risk of Hall RG; Cole TJ; Shaw C; Alvarez CA Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759 [TBL] [Abstract][Full Text] [Related]
19. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection. Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526 [TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis. Okumura H; Fukushima A; Taieb V; Shoji S; English M J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]